Moderna is trading at $160.30, up +10.08%, as U.S. markets recover after the Federal Reserve’s September 16 rate hike, which removed immediate policy uncertainty and improved risk appetite.
- Major indexes are up more than 0.5%, while biotechnology is gaining 2.55% amid stronger industry demand and M&A optimism.
- Recent cancer-vaccine news remains supportive background, but no new company-specific catalyst was identified for September 17.